ENTELLUS MEDICAL INC

Operating margin

−37.7%

Net margin

−40.7%

Return on equity

−19.4%

Return on assets

−9.5%

Return on capital (ROCE)

−13.5%

Liabilities / assets

50.8%

Debt / equity

1.03×

Book value / share

$1.89

Revenue growth (YoY)

25.2%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

-3.67distress

Accruals / assets

18.3%high accruals

Beneish M-Score

151.75elevated

Piotroski F-Score

2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 28, 2018
• Shareholder voteFeb 26, 2018
• Other material eventJan 4, 2018
• Entered a material agreement · Regulation FD disclosureDec 7, 2017
• Results of operations · Director / officer changeNov 1, 2017
• Other material eventSep 25, 2017
• Regulation FD disclosureAug 8, 2017
• Results of operationsAug 3, 2017

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.